What is Genome Medical?
Genome Medical operates as a telehealth-based medical practice, leveraging a combination of face-to-face video, email, texting, shared imaging, and mobile applications to deliver comprehensive clinical health care and patient education remotely. Headquartered in South San Francisco, the company aims to enhance accessibility and efficiency in healthcare delivery. Its services support both patient care and professional health-related education, as well as public health and health administration initiatives, positioning it as a key player in the evolving landscape of digital health solutions.
How much funding has Genome Medical raised?
Genome Medical has raised a total of $120M across 3 funding rounds:
Series A
$23M
Series B
$37M
Series C
$60M
Series A (2017): $23M with participation from HealthInvest Equity Partners, Canaan Partners, Flywheel Ventures, and Illumina Ventures
Series B (2020): $37M led by Dreamers Fund, Illumina Ventures, Echo Health Ventures, Samsung Electronics America, Kaiser Permanente Ventures, LRVHealth, Canaan Partners, HealthInvest Equity Partners, Flywheel Ventures, Perceptive Advisors, GE Ventures, Revelation Partners, Avestria Ventures, Manatt Venture Fund, Randy Scott, and Casdin Capital
Series C (2021): $60M supported by Amgen Ventures, Canaan Partners, Perceptive Advisors, Kaiser Permanente Ventures, Casdin Capital, and GV
Key Investors in Genome Medical
Illumina Ventures
Illumina Ventures is a leader in genomics and precision health investing, focused on building an ecosystem that translates investment into innovation to enhance human health. The company supports various portfolio companies that are advancing life science research, biopharmaceutical drug development, and gene editing technologies.
Kaiser Permanente Ventures
Kaiser Permanente Ventures is a national leader in strategic venture investing in healthcare, focusing on advancing healthcare innovation. The company partners with entrepreneurs to build promising healthcare solutions that provide clear value for patients, providers, and healthcare delivery systems.
Canaan Partners
Canaan is an early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages in areas such as enterprise software, fintech, consumer, biopharma, and digital health.
What's next for Genome Medical?
With the recent influx of $60M in a major strategic investment, Genome Medical is poised for accelerated growth and enhanced service capabilities. This funding, part of its overall $120M in capital, suggests a strong investor confidence in the company's model for delivering integrated telehealth services. The company is likely to focus on expanding its technological infrastructure, broadening its service reach, and potentially exploring new partnerships to further solidify its presence in the genomics and precision health market. Future developments may include advancements in its platform's analytical tools and patient engagement features, aiming to redefine remote healthcare delivery.
See full Genome Medical company page
